Literature DB >> 7863265

Aberrant patterns of immunoglobulin levels in Wiskott-Aldrich syndrome.

R Inoue1, N Kondo, N Kuwabara, T Orii.   

Abstract

We have investigated IgM deficiency in Wiskott-Aldrich syndrome patients. From the assessment of T and B cell functions in pokeweed mitogen-induced immunoglobulin (Ig) production, IgM deficiency was chiefly thought to result from B cell dysfunction. The percentages of surface IgM-bearing cells were decreased in peripheral blood mononuclear cells (PBMCs) and the number of IgM-secreting cells was also decreased. Lymphoblast cell lines (LCLs) from the patients have produced IgG and IgA, but never IgM. Moreover the expression of the C mu transcript from the patients' PBMCs and their LCLs were decreased, whereas the C gamma gene was well expressed. No germ-line polymorphism existed between the patients and the controls in the C mu region, and no mutation was detected in the mu s C-terminal and the M exon by nucleotide sequencing. These suggest that the Ig heavy chain (IGHC) isotype switch may be abnormally accelerated in the patients' B cells. While the methylation patterns of the human Ig enhancer gene region were the same between the patient and the control, the methylation patterns of the I gamma 1 region showed less methylation in the patient than in the control, which may cause low IgM expression and high expression levels of other classes located downstream of the IGHC gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7863265     DOI: 10.1111/j.1365-3083.1995.tb03552.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Management of Wiskott-Aldrich syndrome.

Authors:  A Srivastava; H A Swaid; M Kabra; I C Verma
Journal:  Indian J Pediatr       Date:  1996 Sep-Oct       Impact factor: 1.967

2.  Low T Cell Numbers Resembling T-B+ SCID in a Patient with Wiskott-Aldrich Syndrome and the Outcome of Two Hematopoietic Stem Cell Transplantations.

Authors:  Deniz Cagdas; Selin Aytac; Barış Kuskonmaz; Tadashi Ariga; Mirjam van der Burg; Duygu Uckan Cetinkaya; Özden Sanal; İlhan Tezcan
Journal:  J Clin Immunol       Date:  2016-11-30       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.